3 completed, 3 not yet recruiting, 3 recruiting, 1 unknown. 6 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 3, Recruiting 2, Unknown 1 |
| Phase 1 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow glumetinib: new trials by email Literature Review of glumetinib trials Research Report on glumetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors Glumetinib Tablets, Docetaxel for Injection (Albumin-bound) - Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Phase 2 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 350 | 2025-06-04 | 2025-09-08 |
| A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs Glumetinib, Osimertinib mesylate, Pemetrexed - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 350 | 2025-04-03 | 2025-04-08 |
| Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients Glumetinib Tablets, Osimertinib Mesylate Tablets, Glumetinib Tablets Placebo - Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 390 | 2025-04-01 | 2025-04-03 |
| A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer Glumetinib tablets, HB1801 (docetaxel, albumin-bound), Docetaxel - Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 256 | 2024-07-01 | 2024-07-29 |
| Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. gumarontinib, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 91 | 2024-06-01 | 2024-06-11 |
| Single Dose Glumetinib in Healthy Chinese Male Subjects Glumetinib - Healthy Volunteers | Phase 1 | Completed | Haihe Biopharma Co., Ltd. | 18 | 2021-03-02 | 2022-08-19 |
| Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors Glumetinib - Negative T790M Mutation and Met Amplification | Phase 1 / Phase 2 | Unknown | Haihe Biopharma Co., Ltd. | 70 | 2019-11-18 | 2020-04-08 |
| Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer Glumetinib - C-Met Exon 14 Mutation | Phase 1 / Phase 2 | Recruiting | Haihe Biopharma Co., Ltd. | 183 | 2019-07-15 | 2022-08-01 |
| A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors Gumarontinib Tablets - Advanced Solid Tumor | Phase 1 | Completed | Haihe Biopharma Co., Ltd. | 177 | 2017-12-16 | 2024-11-01 |
| Study to Evaluate the Safety and Anti-tumor Activity of SCC244 Gumarontinib Tablets - Advanced Solid Tumor | Phase 1 | Completed | Haihe Biopharma Co., Ltd. | 56 | 2017-09-14 | 2024-10-09 |
Carcinoma, Non-Small-Cell Lung (2) · Recurrence (2)
Haihe Biopharma Co., Ltd. (5) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Shanghai JMT-Bio Inc. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
China (7) · Japan (1) · United States (1)
Dingzhi Huang, Doctor (1) · Fugen Li (1) · James Zhou, MD (1) · Jianying Zhou, Doctor (1) · Jie Wang, PhD (1) · Yilong Wu, M.D. (1) · Yiping Zhang, Doctor (1) · Yongqian Shu, Doctor (1)
PMID 39091606, PMID 20610543, PMID 26808342, PMID 30207593, PMID 37096188, PMID 41132955